131 related articles for article (PubMed ID: 2689681)
1. [Therapy by biological response modifiers].
Urushizaki I
Rinsho Ketsueki; 1989 Aug; 30(8):1230-2. PubMed ID: 2689681
[TBL] [Abstract][Full Text] [Related]
2. [Recent trends in cancer treatment using cytokines].
Urushizaki I
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
[TBL] [Abstract][Full Text] [Related]
3. [Tumoricidal biological response modifiers (BRM)].
Niitsu Y; Kohgo Y; Watanabe N
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1407-13. PubMed ID: 1697152
[TBL] [Abstract][Full Text] [Related]
4. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer].
Wirth M
Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729
[TBL] [Abstract][Full Text] [Related]
5. Prospects for interleukin-2 therapy in hematologic malignant neoplasms.
Malkovska V; Sondel PM
J Natl Cancer Inst Monogr; 1990; (10):69-72. PubMed ID: 2189478
[TBL] [Abstract][Full Text] [Related]
6. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
7. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
Ozdemir O; Savaşan S
Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
9. [Receptor-mediated cancer therapy--tumoricidal cytokines, adoptive therapy of LAK, TIL].
Niitsu Y; Watanabe N; Kondo H; Kanisawa Y
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1134-41. PubMed ID: 1693487
[TBL] [Abstract][Full Text] [Related]
10. [Palliative therapy in cancer. 6. Quality of life and BRM therapy in cancer-patients].
Urushizaki I
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2119-29. PubMed ID: 1699499
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
Tahara H; Lotze MT
Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
[TBL] [Abstract][Full Text] [Related]
12. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
13. Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy.
Heaton KM; Ju G; Grimm EA
Cancer Res; 1993 Jun; 53(11):2597-602. PubMed ID: 8495422
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo.
Christ O; Matzku S; Burger C; Zöller M
Clin Cancer Res; 2001 May; 7(5):1385-97. PubMed ID: 11350910
[TBL] [Abstract][Full Text] [Related]
15. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
17. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
19. Cancer therapy by biological response modifiers.
Herberman RB
Clin Physiol Biochem; 1987; 5(3-4):238-48. PubMed ID: 2441918
[TBL] [Abstract][Full Text] [Related]
20. [Interleukin-2 and cancer treatment].
Taguchi T
Gan To Kagaku Ryoho; 1986 Jan; 13(1):1-10. PubMed ID: 3510586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
